PEARL Study Protocol: a Real-World Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine

Messoud Ashina1 Department of Neurology, Danish Headache Center, Rigshospitalet, Glostrup, 2600, DenmarkCorrespondence[email protected]

https://orcid.org/0000-0003-0951-5804 View further author information

Faisal Mohammad Amin1 Department of Neurology, Danish Headache Center, Rigshospitalet, Glostrup, 2600, Denmark;2 Faculty of Health & Medical Sciences, University of Copenhagen1, Copenhagen, 2200, DenmarkView further author information

Pinar Kokturk3 Teva Netherlands B.V., BR, Amsterdam, 1019, The NetherlandsView further author information

Joshua M Cohen4 Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA19380, USAView further author information

Martijn Konings3 Teva Netherlands B.V., BR, Amsterdam, 1019, The NetherlandsView further author information

Cristina Tassorelli5 Department of Brain & Behavioral Sciences, University of Pavia, Pavia, 27100, Italy;6 Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation1, Pavia, 27100, ItalyView further author information

Leonidas Lyras3 Teva Netherlands B.V., BR, Amsterdam, 1019, The NetherlandsView further author information

Dimos-Dimitrios Mitsikostas7 Department of First Neurology, Aeginition Hospital, Medical School, National & Kapodistrian University of Athens, Athens, 11528, GreeceView further author information

show all

PEARL Study Protocol: a Real-World Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine

Infographic

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

PEARL Study Protocol: a Real-World Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine

Infographic

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date